Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry

ObjectiveChronic hepatitis C virus infection is associated with a significant health burden. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The introduction of direct-acting antivirals (DAA) has led to an increase in sustained virologic response rates (SV

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Krüger, Kathrin (VerfasserIn) , Pathil-Warth, Anita (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: February 2019
In: European journal of gastroenterology & hepatology
Year: 2019, Jahrgang: 31, Heft: 2, Pages: 230-240
ISSN:1473-5687
DOI:10.1097/MEG.0000000000001283
Online-Zugang:Verlag, Volltext: https://doi.org/10.1097/MEG.0000000000001283
Volltext
Verfasserangaben:Kathrin Krüger, Christian Krauth, Siegbert Rossol, Stefan Mauss, Klaus Boeker, Tobias Müller, Hartwig Klinker, Anita Pathil, Renate Heyne, Jona Stahmeyer, and Collaborators DHC-R
Beschreibung
Zusammenfassung:ObjectiveChronic hepatitis C virus infection is associated with a significant health burden. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The introduction of direct-acting antivirals (DAA) has led to an increase in sustained virologic response rates (SV
Beschreibung:Gesehen am 29.11.2019
Beschreibung:Online Resource
ISSN:1473-5687
DOI:10.1097/MEG.0000000000001283